Spanish biotech SpliceBio has raised $135 million in financing that will help it move a gene-editing therapy for an inherited retinal disease (IRD) through clinical testing. SpliceBio's lead in-house ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback